Abstract
Overview
Introduction
Detailed analysis of the antiretroviral therapy market. 10 year sales forecast
for marketed drugs and key pipeline compounds, factoring in clinical trial
results, new product launches and patent expiries.
Scope
- In-depth analysis of the current HIV market across the major US and EU
markets
- Thorough assessment of underlying commercial and clinical factors shaping
the antiretroviral market
- Detailed sales forecasts for the three major antiretroviral classes,
molecules and brands in each of the six major markets
- Case study analysis of the entry inhibitor class focusing on the
competitive environment and critical success factors
Report Highlights
By 2016 the HIV market is forecasted to grow to $11.5 billion. This growth
will be driven mainly by the increase in numbers of patients accessing
treatments as well as the launch of several new drugs and drug classes
The availability of several simple, once-daily treatments such as fixed dose
combinations and once daily protease inhibitors has intensified the
competition within the respective classes. Adherence to therapy is
consequently expected to improve leading to a decline in the number of
patients entering late-stage therapy.
The anticipated launches of pipeline antiretrovirals such as CCR5 inhibitors,
integrase inhibitors and others, which demonstrate novel activity and efficacy
against resistant mutants, will not only offer more variety to patients but
will increase the overall value of the market.
Reasons to Purchase
- Understand the constantly evolving market dynamics of antiretroviral drugs
- Understand the impact of pending patent expiries and generic incursion on
the ARV market, including product-specific case studies
- Obtain full global, country, class and product-specific forecasts of
currently marketed and pipeline antiretrovirals from 2006 to 2016.
| 
View Cart
